Drug intelligence / Profile preview

BMS-914832

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-914832 is an investigational drug developed by Bristol Myers Squibb. It has been studied in clinical trials as a potential treatment for atrial fibrillation, specifically to assess its pharmacokinetics and possible interactions with other drugs such as diltiazem. The precise mechanism of action, molecular target, and chemical class of BMS-914832 have not been publicly disclosed in available sources. Its development appears to be limited to early-phase clinical studies focused on cardiovascular indications.

Beyond the preview

Go deeper on BMS-914832.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-914832.

Explore the full profile